Trovagene
Cardiff Oncology Doses First Patient in Phase II Onvansertib Trial in Pancreatic Cancer
The firm will assess its anti-PLK1 agent plus chemo as second-line treatment and will measure patients' KRAS allelic burden via liquid biopsy.
The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.
Trovagene Sees Signs of Efficacy for Onvansertib in AR-V7 Castration-Resistant Prostate Cancer
Data from an ongoing study suggests that the drug, combined with an androgen receptor signaling inhibitor, may be efficacious in a particularly hard to treat form of prostate cancer.
Trovagene Starts Onvansertib Trial in KRAS-Mutated Colorectal Cancer
In the 44-patient study, onvansertib will be studied in combination with Avastin and FOLFIRI in the second-line metastatic colorectal cancer setting.